Compare PepsiCo, Inc. (PEP) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs 10X Genomics Inc — how do they compare? PepsiCo, Inc. trades at $127.51 (market cap $174.89B), while 10X Genomics Inc trades at $78.99 (market cap $10.07B). The key difference: PepsiCo, Inc. is far larger — about 17.4× 10X Genomics Inc's market cap, and PepsiCo, Inc. pays a 4.61% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and 10X Genomics Inc for 92 Days on average.
| PEP | TXG | |
|---|---|---|
Market Cap | $174.89B | $10.07B |
Volume | 23,968,864 | 5,657,286 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $97.74 |
52-Week Low | $123.64 | $11.48 |
Typical Hold Time | 107 Days | 92 Days |
Enterprise Value | $215.61B | $9.59B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $123.64, down 1.65% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $2.34 exceeding expectations. Revenue growth remains steady at $93.93B for 2025, though net income margin declined to 8.77%. Recent news highlights price adjustments for snack products and sponsorship changes.
PepsiCo presents a mixed investment case with strong profitability metrics (ROE 51.59%) and analyst consensus price target of $146.77 (18.7% upside), but faces headwinds from consumer price sensitivity and technical weakness. The company's cash flow stability and dividend payments provide defensive characteristics, though execution risks in North American markets warrant monitoring.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
